Biocon Q1FY27: Consolidated PAT Up 53% YoY to ₹137 Cr as BBL Becomes Wholly Owned

Biocon's consolidated (primary basis) total income for Q1 FY27 came in at ₹4,390.5 Cr, up 9.2% YoY (₹4,021.6 Cr), with revenue from operations rising 10.0% YoY to ₹4,336.0 Cr, though down 4.0% sequentially from Q4 FY26's ₹4,516.6 Cr. Group profit for the period (before the owners/non-controlling-interest split) was ₹136.8 Cr, up 53.4% YoY from ₹89.2 Cr; stripping out one-off exceptional items on both sides (a ₹13.5 Cr Syngene termination-benefits charge this quarter versus a ₹17.2 Cr litigation-settlement charge a year ago), underlying PAT growth was a still-solid 43.8% (₹146.8 Cr vs ₹102.1 Cr adjusted). Net profit margin expanded to 3.12% from 2.22% YoY. Management's own release headlines "Net Profit ₹141 Cr" — that figure is profit attributable to shareholders (₹141.1 Cr), which differs from the ₹136.8 Cr group total because BBL, previously partly minority-held, became a wholly owned subsidiary on June 29, 2026, largely eliminating the non-controlling interest that had absorbed ₹57.8 Cr of group profit in the year-ago quarter.

The margin story is a mix by segment. Biosimilars, the group's largest segment, grew revenue 16.2% YoY to ₹2,855.6 Cr with segment PBT of ₹171.4 Cr (margin ~6.0%, still well below management's guided mid-20s full-year level). Generics revenue rose 20.5% YoY to ₹759.7 Cr and its segment loss narrowed sharply to ₹30.9 Cr from ₹101.6 Cr. Offsetting these gains, the Services segment (Syngene/CRDMO) — flagged in the prior concall as facing "transient headwinds" — saw revenue fall 15.8% YoY to ₹736.0 Cr and swung to a ₹5.7 Cr segment loss from a ₹101.3 Cr profit a year ago, confirming that guidance directionally. Consolidated finance costs fell 22.9% YoY to ₹213.2 Cr, an early sign of the ~₹300 Cr annualized interest savings management guided from FY27 following its debt paydown.

The stock went into the print at ₹425.2, up 4.5% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.

NPM expanded to 3.12% from 2.22% YoY — EBITDA-based OPM roughly steady at ~19.5% vs ~19.4% YoY

On street context, TradingView's pre-result consensus had pencilled in revenue near ₹4,482 Cr and EPS of ₹0.49 for the quarter; actual total income landed about 2% light of that at ₹4,391 Cr while EPS of ₹0.87 beat the estimate by roughly 77% — a clear profitability beat against a softer revenue print. Standalone (parent-only, secondary) results swung to a ₹52.2 Cr profit from an ₹8.3 Cr loss in Q1 FY26, aided by the absence of exceptional items this quarter.